SCHEMBL770324

SCHEMBL770324

O=C(O)CCS(=O)(=O)N1CCCC2CCCC=C21

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
CNR1 P21554 3/20 0.32
ALDH1A1 P00352 1/20 0.31
MMP1 P03956 1/20 0.31
MMP7 P09237 1/20 0.31
MMP8 P22894 1/20 0.31
MMP12 P39900 1/20 0.31
MMP13 P45452 1/20 0.31
KDM4E B2RXH2 2/20 0.30
GLA P06280 1/20 0.30
FKBP1A P62942 2/20 0.30
USP5 P45974 2/20 0.30
HDAC6 Q9UBN7 2/20 0.30
APEX1 P27695 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C19 P33261 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770852 0.92 FFAR4 (0.33) ALDH1A1FKBP1A
SCHEMBL770345 0.85 SMYD3 (0.37) HTTALDH1A1MMP8MMP12MMP13
SCHEMBL770150 0.80 POLB (0.40) HTTNPSR1ALDH1A1NPC1RAB9A
SCHEMBL771132 0.80 POLB (0.40) HTTNPSR1ALDH1A1NPC1RAB9A
SCHEMBL771792 0.80 ALDH1A1 (0.35) ALDH1A1MMP8MMP12MMP13GLA
SCHEMBL770148 0.80 POLB (0.40) HTTNPSR1ALDH1A1NPC1RAB9A
SCHEMBL770641 0.78 CHRM2 (0.35) ALDH1A1NPC1RAB9AKMT2A
SCHEMBL770815 0.78 ALDH1A1 (0.31) ALDH1A1NPC1RAB9A
SCHEMBL770874 0.78 NPC1 (0.47) HTTALDH1A1NPC1RAB9AKMT2A
SCHEMBL770783 0.77 PDE3B (0.38) NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HTT 412/4885NPSR1 1890/4885CNR1 1805/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HTT 425/4885NPSR1 1896/4885CNR1 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.